Exercise and prostate cancer: Evidence and proposed mechanisms for disease modification

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 9, 2016, Pages 1281-1288

  Hayes, Brian D ^a,b   Brady, Lauren ^b   Pollak, Michael ^c   Finn, Stephen P ^b,d  

^a Department of Medicine National University of Ireland Cork   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c MCGILL UNIVERSITY   (Canada)

^d ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE;

CANCER PATIENT; CIRCULATING TUMOR CELL; EVIDENCE BASED MEDICINE; EXERCISE; HUMAN; MALE; METABOLIC SYNDROME X; NATURAL KILLER CELL; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKELETAL MUSCLE; THROMBOCYTE; CARDIOVASCULAR DISEASE; COMPLICATION; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; QUALITY OF LIFE; RISK FACTOR; TUMOR EMBOLISM;

ADIPOKINES; CARDIOVASCULAR DISEASES; EXERCISE; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; OBESITY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS;

EID: 84986184049     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0223     Document Type: Review

References (99)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 2010;4:87-100.
3. Voskuil DW, Monninkhof EM, Elias SG, Vlems FA, van Leeuwen FE; Task force physical activity and cancer. Physical activity and endometrial cancer risk, a systematic review of current evidence. Cancer Epidemiol Biomarkers Prev 2007;16:639-48.
4. Boyle T, Keegel T, Bull F,Heyworth J, Fritschi L. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst 2012;104:1548-61.
5. Keimling M, Behrens G, Schmid D, Jochem C, Leitzmann MF. The association between physical activity and bladder cancer: a systematic review and meta-analysis. Br J Cancer 2014;110:1862-70.
6. Behrens G, Leitzmann MF. The association between physical activity and renal cancer: systematic review and meta-analysis. Br J Cancer 2013;108: 798-811.
7. Behrens G, Jochem C, Keimling M, Ricci C, Schmid D, Leitzmann MF. The association between physical activity and gastrooesophageal cancer: systematic review and meta-analysis. Eur J Epidemiol 2014;29:151-70.
8. Wu Y, Zhang D, Kang S. Physical activity and risk of breast cancer: a meta-analysis of prospective studies. Breast Cancer Res Treat 2013;137: 869-82.
9. Jochem C, Leitzmann MF, Keimling M, Schmid D, Behrens G. Physical activity in relation to risk of hematologic cancers: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:833-46.
10. Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, et al. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 2008;26: 907-12.
11. Tomlinson D, Diorio C, Beyene J, Sung L. Effects of exercise on cancer-related fatigue: a meta-analysis. Am J Phys Med Rehabil 2014; 93:675-86.
12. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2012;11:CD006145.
13. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database of Syst Rev 2012;8: CD008465.
14. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddigi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer surivivors: a systematic review. J Natl Cancer Inst 2012;104:815-40.
15. Irwin ML, McTiernan A, Manson JE, Thomson CA, Sternfeld B, Stefanick ML, et al. Physical activity and survival in postmenopausal women with breast cancer: results from the women's health initiative. Cancer Prev Res 2011;4:522-9.
16. West-Wright CN, Henderson KD, Sullivan-Halley J, Ursin G, Deapen D, Neuhausen S, et al. Long-term and recent recreational physical activity and survival after breast cancer: the California Teachers Study. Cancer Epidemiol Biomarkers Prev 2009;18:2851-9.
17. Haydon AMM, MacInnis RJ, English DR, Giles GG. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 2006;55:62-7.
18. Meyerhardt JA, Giovannucci EL, Ogino S, Kirkner GJ, Chan AT, Willett W, et al. Physical activity andmale colorectal cancer survival. Arch Intern Med 2009;169:2102-8.
19. Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan JA, Colditz GA, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 2006;24:3527-34.
20. Courneya KS, Friedenreich CM, Franco-Villalobos C, Crawford JJ, Chua N, Basi S, et al. Effects of supervised exercise on progression-free survival in lymphoma patients: an exploratory follow-up of the HELP trial. Cancer Causes Control 2015;26:269-76.
21. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the Health Professionals Follow-Up Study. Int J Cancer 2007;121:1571-8.
22. Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ, Elliott FG. Case-Control study of lifetime total physical activity and prostate cancer risk. Am J Epidemiol 2004;159:740-9.
23. Johnsen NF, Tjønneland A, Thomsen BL, Christensen J, Loft S, Friedenreich C, et al. Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Int J Cancer 2009;125:902-8.
24. Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ, Willett WC. A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med 2005;165:1005-10.
25. Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ, Calle EE. Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomarkers Prev 2005;14:275.
26. Littman AJ, Kristal AR, White E. Recreational physical activity and prostate cancer risk (United States). Cancer Causes Control 2006;17: 831-41.
27. Nilsen TI,Romundstad PR, Vatten LJ. Recreational physical activity and risk of prostate cancer: A prospective population-based study in Norway (the HUNT study). Int J Cancer 2006;119:2943-7.
28. Wiklund F, Lageros YT, Chang E, Balter K, Johansson JE, Adami HO, et al. Lifetime total physical activity and prostate cancer risk: a population-based case-control study in Sweden. Eur J Epidemiol 2008;23:739-46.
29. Zeegers MA, Dirx MJM, Van Den Brandt PA. Physical activity and the risk of prostate cancer in the Netherlands Cohort Study, results after 9.3 years of follow-up. Cancer Epidemiol Biomarkers Prev 2005;14:1490-5.
30. Keogh JWL, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom Manage 2012;43: 96-110.
31. Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatmentrelated adverse effects for patients with prostate cancer receiving androgendeprivation therapy: a systematic review. J Clin Oncol 2014;32:335-46.
32. Kapur G, Windsor PM, McCowan C. The effect of aerobic exercise on treatment-related acute toxicity in men receiving radical external beam radiotherapy for localized prostate cancer. Eur J Cancer Care (Engl) 2010;19:643-7.
33. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG, et al. Randomised controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009;27: 344-51.
34. Culos-Reed SN, Robinson JW, Lau H, Stephenson L, KeatsM, Norris S, et al. Physical activity for men receiving androgen deprivation therapy for prostate cancer: benfits from a 16-week intervention. Support Care Cancer 2010;18:591-9.
35. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the Health Professionals Follow-Up Study. J Clin Oncol 2011;29:726-32.
36. Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the Cancer of the prostate strategic urologic research endeavor. Cancer Res 2011;71:3889-95.
37. Bonn SE, Sjolander A, Lagerros YT, Wiklund F, Stattin P, Holmberg E, et al. Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev 2015;24:57-64.
38. Friedenreich CM, Wang Q, Neilson HK, Kopciuk KA, McGregor SE, Courneya KS. Physical activity and survival after prostate cancer. Eur Urol 2016 Jan 7. [Epub ahead of print].
39. Sellar CM, Bell GJ, Haennel RG, Au HJ, Chua N, Courneya KS. Feasibility and efficacy of a 12-week supervised exercise intervention for colorectal cancer survivors. Appl Physiol Nutr Metab 2014;39:715-23.
40. Peddle-McIntyre CJ, Bell G, Fenton D, McCargar L, Courneya KS. Feasibility and preliminary efficacy of progressive resistance exercise training in lung cancer survivors. Lung Cancer 2012;75:126-32.
41. Broderick J, Guinan E, Kennedy MJ, Hollywood D, Courneya KS, Culos-Reed N, et al. Feasibility and efficacy of a supervised exercise intervention in de-conditioned cancer survivors during the early survivorship phase: the PEACH trial. J Cancer Surviv 2013;7:551-62.
42. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014;311:806-14.
43. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M,Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261-7.
44. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 2003;104:195-201.
45. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91: 1305-8.
46. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102:39-46.
47. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.
48. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24:3979-83.
49. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol 2010;28:3448-56.
50. Smith MR, Bae K, Efstathiou JA, Hanks GE, PilepichMV, Sandler HM, et al. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol 2008;26:4333-9.
51. Ma J, Li H, Giovannucci E,Mucci L, QiuW, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancerspecific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008;9:1039-47.
52. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:1646-50.
53. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006;164:1094-102.
54. Aggarwal RR, Ryan CJ, Chan JM. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? Urol Oncol 2013;31: 522-30.
55. Luo J, Murphy LJ. Differential expression of the insulin-like growth factor binding proteins in spontaneously diabetic rats. J Mol Endocrinol 1992;8: 155-63.
56. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is upregulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62:2942-50.
57. Ryan CJ, Hagg CM, Simko J, Nonaka DF, Chan JM, Weinberg V, et al. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol 2007;25:134-40.
58. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014;105:141-50.
59. Zhang N, Lawrence DA. Tissue factor and obesity, a two-way street. Nat Med 2011;17:1343-4.
60. Badeanlou L, Furlan-Freguia C, Yang G, Ruf W, Samad F. Tissue factorprotease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. Nat Med 2011;17:1490-8.
61. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
62. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111: 1448-54.
63. Rundqvist H, Augsten M, Stromberg A, Rullman E, Mijwel S, Kharaziha P, et al. Effect of acute exercise on prostate cancer cell growth. PLoS ONE 2013;8:e67579.
64. Soliman S, Aronson WJ, Barnard RJ. Analyzing serum-stimulated prostate cancer cell lines after low-fat, high-fibre diet and exercise intervention. Evid Based Complement Alternat Med 2011;2011:529053.
65. Leung PS, Aronson WJ, Ngo TH, Golding LA, Barnard RJ. Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumour cells in vitro. J Appl Physiol 2004;96:450-4.
66. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005;174:1065-70.
67. Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, Fels D, et al. Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. J Appl Physiol 2012;113:263-72.
68. Zheng X, Cui XX, Huang MT, Liu Y, Shih WJ, Lin Y, et al. Inhibitory effect of voluntary running wheel exercise on the growth of human pancreas Panc-1 and prostate PC-3 xenograft tumors in immunodeficient mice. Oncol Rep. 2008;19:1583-8.
69. Ho SS, Dhaliwal SS, Hills AP, Pal S. Effects of chronic exercise training on inflammatory markers in Australian overweight and obese individuals in a randomized controlled trial. Inflammation 2012 Dec 19. [Epub ahead of print].
70. Balducci S, Zanuso S, Nicolucci A, Fernando F, Cavallo S, Cardelli P, et al. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercisemodalities and independent of weight loss. Nutr Metab Cardiovasc Dis 2010;20: 608-17.
71. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomised controlled trial. J Clin Oncol 2010;28: 340-7.
72. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNFa correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004;90:2312-6.
73. Radhakrishnan P, Chachadi V, Lin MF, Singh R, Kannagi R, Cheng PW. TNFa enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl-and sulfotransferase genes involved in the synthesis of selectin ligands. Biochem Biophys Res Comm 2011;409:436-41.
74. Restituto P, Colina I, Varo JJ, Varo N. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in themetabolic syndrome. Am J Physiol Endocrinol Metab 2010;298:E1072-7.
75. Ismail HA, Lessard L, Mes-Masson AM, Saad F. Expression ofNF-kappaB in prostate cancer lymph node metastases. Prostate 2004;58:308-13.
76. Lynch LA, O'Connell JM, Kwasnik AK, Cawood TJ, O'Farrelly C,O'Shea DB. Are natural killer cells protecting the metabolically healthy obese patient? Obesity 2009;17:601-5.
77. Lautenbach A, Breitmeier D, Kuhlmann S, Nave H. Human obesity reduces the number of hepatic leptin receptor (Ob-R) expressing NK-cells. Endocr Res 2011;36:158-66.
78. Timmons BW, Cieslak T. Human natural killer cell subsets and acute exercise: a brief review. Exerc Immunol Rev 2008;14:8-23.
79. Radom-Azik S, Zaldivar FP, Haddad F, Cooper DM. Impact of brief exercise on peripheral blood NK-cell gene and microRNA expression in young adults. J Appl Physiol. 2013 Jan 3. [Epub ahead of print].
80. Wang JS, Weng TP. Hypoxic exercise training promotes antitumour cytotoxicity of natural killer cells in young men. Clin Sci 2011;121:343-53.
81. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.
82. De Bono, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment inmetastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
83. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castrationresistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009;10:233-9.
84. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123-34.
85. Egan K, Crowley D, Smyth P, O'Toole S, Spillane C,Martin C, et al. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signaling in ovarian cancer cells. PLoS One 2011;6:e26125.
86. Nieswandt B, Hafner M, Echtenacher B,Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59: 1295-300.
87. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005;105:178-85.
88. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factorb down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009;69:7775-83.
89. Placke T, Orgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumour reactivity of natural killer immune cells. Cancer Res 2012;72:440-48.
90. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007;110:133-41.
91. Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, et al. Factor XIII transglutaminase supports haematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost 2008;6:812-9.
92. Babiker AA, Hamad OA, Sanchez J, Ronquist G, Nilsson B, Nilsson Ekdahl K. Prothrombotic effect of prostasomes of metastatic cell and seminal origin. Prostate 2007;67:378-88.
93. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 2013;24:130-7.
94. Zhang W, Dang S, Hong T, Tang J, Fan J, Bu D, et al. A humanized singlechain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood 2012;120:2889-98.
95. Ware J. Fragmenting the platelet to reduce metastasis. Blood 2012;120: 2779-80.
96. Labelle M, Begum S, Hynes RO. Direct signalling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011;20:576-90.
97. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012;8:457-65.
98. Padhi D, Higano CS, Shore ND, Sieber P, Rasmussen E, Smith MR. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2014;99:E1967-75.
99. Liu Y, Cheng H, Zhou Y, Zhu Y, Bian R, Chen Y, et al. Myostatin induces mitochondrial metabolic alteration and typical apoptosis in cancer cells. Cell Death Dis 2013;4:e494